|LETTER TO THE EDITOR
|Year : 2021 | Volume
| Issue : 4 | Page : 787-788
Authors' reply to Gupta et al.
Joydeep Ghosh, Sandip Ganguly, Bivas Biswas
Departments of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
|Date of Submission||18-Nov-2021|
|Date of Decision||23-Nov-2021|
|Date of Acceptance||20-Dec-2021|
|Date of Web Publication||29-Dec-2021|
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Ghosh J, Ganguly S, Biswas B. Authors' reply to Gupta et al. Cancer Res Stat Treat 2021;4:787-8
We would like to thank Gupta and Kapoor for reading our article with interest and critically analyzing its various aspects. We sincerely appreciate the efforts of the authors on this.
Regarding the first point raised by Gupta and Kapoor, we completely agree that the role of surgery in the treatment journey for gestational trophoblastic neoplasia (GTN) is minimal. Many patients undergo surgery outside, and as rightly pointed out by Gupta and Kapoor, this is still a very common practice in the community. Given the small size of our cohort, we extracted all the previous surgical details and found that none of the three patients who received chemotherapy outside had undergone surgery related to GTN. Hence, we declare with sufficient confidence that none of the patients underwent surgery outside before coming to our center. As we have mentioned in the article, none of the patients underwent surgery at our center. We would like to clarify that we did not mention any patients who were operated on outside and treated at our center subsequently.
Regarding beta human chorionic gonadotropin testing, we went back and discussed with our biochemistry chief, who was of the opinion that if the value lies within the linearity range, we do not need to dilute the sample. However, if it is outside that range, as suggested by the authors, it is routine practice to dilute the sample and confirm the results.
Since this was a retrospective study, we completely agree that we had problems in collecting accurate data on toxicity. However, we have mentioned all the toxicity details that were available from the medical records and reports of blood counts to the best of our capacity.
I hope the authors find our replies satisfactory. We shall be more than happy to clarify any further questions from the authors.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Gupta A, Kapoor A. Gestational trophoblastic neoplasia: A road less travelled. Cancer Res Stat Treat 2021;4:786-7. [Full text]
Ghosh J, Dey S, Mandal D, Ganguly S, Biswas B, Dabkara D, et al.
Clinicopathological features and outcomes of choriocarcinoma: A retrospective analysis from an Indian tertiary cancer center. Cancer Res Stat Treat 2021;4:486-91. [Full text]